Neurenati Therapeutics develops targeted biologics utilizing advanced protein engineering to create a rectal enema treatment for Hirschsprung's disease, a rare gastrointestinal condition affecting young children. This therapy aims to regenerate the enteric nervous system and improve overall intestinal function in patients who currently lack effective treatment options.
Funding
$5.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Hirschsprung's disease, a rare congenital disorder, affects newborns by impairing the enteric nervous system development in the colon, leading to significant intestinal dysfunction. Current treatment options are limited, leaving a critical unmet need for therapies that can regenerate the missing nerve cells and restore normal bowel function.
Solution
Neurenati Therapeutics is developing NEU-001, a targeted biologic administered via rectal enema, designed to regenerate the enteric nervous system in young children with Hirschsprung's disease. This combination therapy utilizes a neurotrophic growth factor to stimulate nerve regeneration in the affected colon. By addressing the underlying cause of the disease, NEU-001 aims to improve overall intestinal function and provide a more effective treatment option for patients who currently lack adequate solutions. The therapy is designed for direct application to the colon, maximizing its impact on the enteric nervous system.
Target Audience
The primary target audience includes newborns and young children diagnosed with Hirschsprung's disease, as well as their families and the medical professionals who treat them, including pediatric gastroenterologists and surgeons.
Features
- Targeted biologic drug administered via rectal enema
- Utilizes a neurotrophic growth factor to stimulate enteric nerve regeneration
- Designed to restore intestinal function in children with Hirschsprung's disease
- Aims to address the underlying cause of the disease by regenerating missing nerve cells
- Intended for direct application to the colon for maximum therapeutic effect